Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ono Pharmaceutical Co has the GF Score of 89, which implies that the company
might have
Good outperformance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Ono Pharmaceutical Co
might have
Good outperformance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Ono Pharmaceutical Co (TSE:4528) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Ono Pharmaceutical Co GF Score Related Terms
TSE:4528 vs LLY, JNJ, ABBV: GF Score Comparison
For the Drug Manufacturers - General subindustry, Ono Pharmaceutical Co's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ono Pharmaceutical Co GF Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ono Pharmaceutical Co's GF Score distribution charts can be found below:
* The bar in red indicates where Ono Pharmaceutical Co's GF Score falls into.
Ono Pharmaceutical Co (TSE:4528) has a GF Score of 89 as of Jul. 14, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Ono Pharmaceutical Co and its competitors. This is near median its historical median of 85.00. Over the past decade, Ono Pharmaceutical Co's GF Score has ranged from 68.00 to 99.00.
Is Ono Pharmaceutical Co's GF Score too high?
Ono Pharmaceutical Co's current GF Score of 89 is near median its 10-year median of 85.00. Over the past 10 years, this metric has ranged from a low of 68.00 to a high of 99.00. Overall, Ono Pharmaceutical Co has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ono Pharmaceutical Co's GF Score compare to LLY and JNJ?
Ono Pharmaceutical Co's GF Score of 89 can be compared against companies in the Drug Manufacturers industry. Historically, Ono Pharmaceutical Co's own GF Score has ranged from 68.00 to 99.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Drug Manufacturers company?
A good GF Score depends on the Drug Manufacturers industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Ono Pharmaceutical Co and its competitors. Ono Pharmaceutical Co's current GF Score is 89, which is near median its own 10-year median of 85.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ono Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Ono Pharmaceutical Co (TSE:4528) is currently considered Fairly Valued. The stock's GF Value™ is 円2,239.11, compared to a current price of 円2,432.50 — trading 8.6% above its estimated fair value. The current GF Score is 89, which is near median its 10-year median of 85.00. Ono Pharmaceutical Co's overall GF Score™ is 89/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Ono Pharmaceutical Co (TSE:4528), the current GF Score is 89 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ono Pharmaceutical Co (TSE:4528) Overvalued in 2026?
Based on GuruFocus' analysis, Ono Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円2,432.50 is trading 8.6% above its estimated GF Value™ of 円2,239.11.
GuruFocus considers Ono Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4528:
GF Score: 89 (near median its 10-year median of 85.00)
GF Value™: 円2,239.11 vs. price of 円2,432.50 (8.6% above fair value)
No single metric tells the full story. See the TSE:4528 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ono Pharmaceutical Co Ltd is a drug manufacturer with a focus on drug discovery in areas of unmet medical needs. The vast majority of the company's revenue is derived from its circulatory and respiratory drugs, followed by its metabolic drugs and vitamins. The company also reports revenue derived from royalties. The bulk of the company's sales is generated in Japan, followed by the rest of Asia and Europe.
89GF Score
Get the complete analysis for TSE:4528
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4528 has been successfully added to your 
